1 Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.
2 Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, Australia.
Int J Stroke. 2018 Aug;13(6):554-567. doi: 10.1177/1747493018765235. Epub 2018 Mar 15.
This review summarizes the current state of knowledge regarding the use of imaging to guide stroke treatment. Brain imaging plays a central role in the diagnosis of stroke and identification of the mechanism of stroke, which is relevant to acute treatment, prognosis, and secondary prevention. The chief potential modalities are computed tomography (CT) and magnetic resonance imaging (MRI). Currently, most imaging occurs in hospital but mobile stroke units have expanded CT brain imaging into the prehospital field. The proven therapies for ischemic stroke are based on achieving reperfusion and the DAWN and DEFUSE 3 trials have now firmly established a need for imaging selection based on estimated ischemic core volume to guide reperfusion decisions in patients beyond 6 h of stroke onset. However, data also indicate that estimated ischemic core volume, in conjunction with patient factors and expected time delay to reperfusion, forms one of the most useful prognostic assessments that could alter decision-making for patients within 6 h. Current trials are also investigating agents that aim to achieve neuroprotection, reduction in edema or prevention of hemorrhagic transformation. Imaging may play a role in identifying patients likely to benefit from this next generation of interventions for stroke patients.
这篇综述总结了目前利用影像学指导卒中治疗的知识现状。脑影像学在卒中的诊断和卒中机制的识别中发挥着核心作用,而后者与急性治疗、预后和二级预防相关。主要的潜在方法是计算机断层扫描(CT)和磁共振成像(MRI)。目前,大多数影像学检查都是在医院进行的,但移动卒中单元已经将 CT 脑部成像扩展到了院前领域。目前,缺血性卒中的已证实疗法基于实现再灌注,而 DAWN 和 DEFUSE 3 试验现在已经明确需要根据估计的缺血核心体积进行影像学选择,以指导发病 6 小时以上的患者的再灌注决策。然而,数据也表明,估计的缺血核心体积,结合患者因素和预期再灌注时间延迟,形成了最有用的预后评估之一,可能会改变发病 6 小时内患者的决策。目前的试验还在研究旨在实现神经保护、减少水肿或预防出血性转化的药物。影像学可能在识别可能受益于卒中患者下一代干预措施的患者方面发挥作用。